Immunomedics, Inc. (IMMU) News

Immunomedics, Inc. (IMMU)

Today's Latest Price: $33.59 USD

0.29 (0.87%)

Updated May 29 4:00pm

Add IMMU to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

Filter IMMU News Items

IMMU News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest IMMU News From Around the Web

Below are the latest news stories about Immunomedics Inc that investors may wish to consider to help them evaluate IMMU as an investment opportunity.

Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19

The Company announces that, after careful consideration, Harout Semerjian has decided to step down from his role as President and Chief Executive Officer (CEO) of Immunomedics. Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics, will continue to support the Company in an executive leadership role going forward. Patient enrollment into the Phase 3 TROPiCS-02 study of Trodelvy in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, has been resumed at approximately 20 clinical sites as of mid-May, with additional sites continuing to open in the coming weeks.

Yahoo | May 27, 2020

3 Charts That Suggest Biotech Stocks Are Headed Higher

Breakouts beyond key levels of resistance suggest that the bulls are in control of the momentum in the biotech sector.

Yahoo | May 20, 2020

Is Immunomedics (IMMU) Stock Outpacing Its Medical Peers This Year?

Is (IMMU) Outperforming Other Medical Stocks This Year?

Zacks Investment Research | May 18, 2020

Immunomedics (IMMU) Q1 Earnings Beat, Trodelvy in Focus

Immunomedics (IMMU) reports a narrower-than-expected Q1 loss. The focus is on its recently approved drug, Trodelvy, for mTNBC.

Zacks Investment Research | May 7, 2020

Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update

Trodelvy™ received accelerated approval from FDA for third-line metastatic triple-negative breast cancer First patient treated with Trodelvy following…

GlobeNewswire | May 6, 2020

Why Immunomedics (IMMU) Might Surprise This Earnings Season

Immunomedics (IMMU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research | May 5, 2020

The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks htitting 52-week highs April 22.) …

Benzinga | April 23, 2020

Thinking about buying stock in Chesapeake Energy Corp, General Electric, Immunomedics, TOP Ships, or United Airlines?

NEW YORK, April 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHK, GE, IMMU, TOPS, and UAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….

PR Newswire | April 23, 2020

Here's Why Immunomedics Shares Are Skyrocketing Today | The Motley Fool

The company won an early FDA approval yesterday for its drug to treat advanced breast cancer.

The Motley Fool | April 23, 2020

Immunomedics wins U.S. FDA approval for breast cancer therapy

Immunomedics Inc on Wednesday won the U.S. Food and Drug Administration approval for its therapy for a form of breast cancer that has worsened despite two prior rounds of treatment, according to the therapy's label from the agency.

Reuters | April 22, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7321 seconds.